Skip to main content
TipRanks
Go Ultimate75% OFF

Biolight (BOLT) AI Stock Analysis

0 Followers
IL:BOLT

Biolight

(TASE:BOLT)

Select Model
Rating:37Underperform
Price Target:ILA 277.00â–¼(-7.67% Downside)
Action:downgraded
Date:08/21/26

The stock scores at the lowest possible level of 37, reflecting severe fundamental and technical distress. The company is pre-revenue with deep losses and significant cash burn, while the stock price is in a strong downtrend across all timeframes. The only positive, a solid balance sheet, is insufficient to offset the overwhelming negative signals from the income statement, cash flows, and market momentum.

Positive Factors
Low LeverageVery low leverage limits refinancing pressure and reduces the risk that interest obligations will overwhelm operating resources. This gives Biolight greater balance-sheet flexibility than a highly indebted medical-device company, although ongoing losses still weaken the overall financial position.
Negative Factors
Minimal and Volatile RevenueExtremely small and volatile revenue indicates that Biolight has not yet demonstrated a dependable commercial base. Zero revenue in 2025 makes it difficult to absorb the existing cost structure, validate product-market traction, or establish a durable path toward operating scale over the next several quarters.

Biolight (BOLT) vs. iShares MSCI Israel ETF (EIS)

-60%-40%-20%0%20%40%IL:BOLT-21.38%EIS+8.23%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
ILS 26.84M
Dividend Yield
―
Average Volume (3M)
10.70K
Price to Earnings (P/E)
-2.2
Beta (1Y)
0.64
Revenue Growth
-100.00%
EPS Growth
-29.02%
Country
Israel
Employees
4
Sector
General
Sector Strength
55
Industry
Medical - Specialties

Biolight Business Overview & Revenue Model

Company Description

BioLight Life Sciences Ltd. is an ophthalmic firm dedicated to discovering, developing, and bringing to market innovative products and pipeline candidates designed to tackle various eye-related ailments. Its portfolio and development pipeline include...

Biolight Financial Statement Overview

Summary

Financial performance is critically weak. The income statement reflects zero revenue and persistent, deep operating losses. Cash flow is consistently negative with significant cash burn. The only mitigating factor is a relatively strong balance sheet with low debt and a recent equity infusion, preventing a score at the absolute floor.

Income Statement

15Very Negative

Balance Sheet

45Neutral

Cash Flow

25Negative
Financial statement breakdown
BreakdownTTMMar 2026Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue00219.00K118.00K63.00K3,000
Gross Profit-270.00K-544.00K219.00K118.00K63.00K3,000
EBITDA-14.65M-14.66M-7.75M-10.08M-8.03M-1.36M
Net Income-11.74M-11.73M-7.14M-26.02M-7.85M382.00K
Balance Sheet
Total Assets35.06M42.41M34.12M33.45M57.01M64.17M
Cash, Cash Equivalents and Short-Term Investments16.19M23.65M13.47M8.64M17.63M33.71M
Total Debt1.06M772.00K599.00K91.00K527.00K443.00K
Total Liabilities3.86M2.24M3.38M3.15M3.32M2.75M
Stockholders Equity28.09M34.40M26.88M29.78M53.17M60.70M
Cash Flow
Free Cash Flow-11.92M-10.86M-11.02M-10.99M-9.64M-10.65M
Operating Cash Flow-11.92M-10.85M-10.99M-9.58M-9.54M-10.03M
Investing Cash Flow-11.96M-16.17M7.55M-1.95M-10.55M13.48M
Financing Cash Flow21.36M21.37M7.98M3.25M-485.00K915.00K

Biolight Technical Analysis

Technical Analysis SentimentNeutral
Last Price300.00

Price Trends

50DMA289.60Positive
100DMA323.78Negative
200DMA317.22Negative

Market Momentum

MACD1.06Negative
RSI53.50Neutral
STOCH92.63Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IL:BOLT, the sentiment is Neutral. The current price of 300.00 is above the 20-day moving average (MA) of 295.15, above the 50-day MA of 289.60, and below the 200-day MA of 317.22, indicating a neutral trend. The MACD of 1.06 indicates Negative momentum. The RSI at 53.50 is Neutral, neither overbought nor oversold. The STOCH value of 92.63 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for IL:BOLT.

Biolight Peers Comparison

Overall Rating

UnderperformOutperform
Sector (55)

Financial Indicators

IL:BOLT against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
Sector *55Neutral$6.65B3.83-15.92%6.20%10.91%7.18%
IL:BLRXIL:BLRX41NeutralILS 29.87M-0.99――-93.07%62.25%
IL:CANFIL:CANF38UnderperformILS 15.75M-0.22――――
IL:BOLTIL:BOLT37UnderperformILS 26.64M-2.19――-100.00%-29.02%

* General Sector Average

Performance Comparison

0%50000%100000%IL:BOLTIL:BONSIL:CBIIL:BLRXIL:CANFDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
IL:BOLT and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
IL:BOLTBioLight Life Sciences Ltd.300.00-84.00-21.88%
IL:BONSBonus Biogroup 15.70-6.20-28.31%
IL:CBIClal Biotechnology Industries Ltd19.80-14.20-41.76%
IL:BLRXBioLineRX Ltd.1.00-0.80-44.44%
IL:CANFCan-Fite BioPharma Ltd.268.70267.7026770.00%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Aug 21, 2026